Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C, Irinotecan and Cetuximab in Metastatic Colorectal Cancer
NCT00271011Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2005
- Primary completion
- Jul 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and KL-140 in metastatic colorectal cancer (mCRC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Objective Response Rate at 2 months. Started Dec 2005; status: terminated.
02
Drugs
mitomycin cirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabKL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00271011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271011.